Steve Engen

CEO, Renexes LLC

---

Steve brings over 25 years of senior executive level operating and transaction experience in the biopharmaceutical industry, with expertise in Japanese/Asian markets.  In 2014, he established his own biopharma consultancy, and continues to support western biopharma clients seeking to execute transactions and other strategic initiatives in Japan. Since establishing his firm, Steve has overseen more than twenty transactions (including buy-side and sell-side transactions) between western and Japanese/Chinese biopharma companies.

 

Steve previously headed the Japanese operations of Shire Pharmaceuticals. Before Shire, Steve served as CEO of Solasia Pharma, a cancer-focused development stage company with operations in Japan and China. Steve launched his biopharma career at Purdue Pharma in business development, and then held the position of President of Mundipharma Japan for nine years. In this role, he oversaw the development and commercialization of the company’s leading pain management franchise.

 

Steve and his wife have two daughters, and currently share time between their homes in Bellevue Washington and Tokyo Japan.  Steve is fluent in written and spoken Japanese.